References
- Finklenstein JZ, Klemperer MR, Evans A. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from the Children's Cancer Study Group. Med Pediatr Oncol 1979; 6: 179–86.
- Graham-Pole J, Casper J, Elfenbein G, et al. High dose chemoradiotherapy supported by marrow infusion for ad-vanced neuroblastoma: a pediatric oncology group study. J Clin Oncol 1991; 9: 152–61.
- Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplan-tation versus continued chemoradiotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996; 14: 2417–26.
- Miller DG, Adam MA, Miller AD. Gene transfer by retro-virus vectors occurs only in cells that are actively replicating at the time of infection. Moll Cell Biol 1990; 10: 4239–42.
- Zwiebel JA, Su N, MacPherson A, Davis T, Ojeifo JO. The gene therapy of cancer: transgenic immunotherapy. Semin Hematol 1993; 30: 119–28.
- Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase gene transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297–300.
- Willis KN, Maneval DC, Menzel P. Development and charac-terization of recombinant adenovirus encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079–88.
- Smith MR, Abubakr U, Mohammad R, Xie T, Hamdan M, al-Katib A. Antisense oligodeoxyribonucleotide down regula-tion of bc1-2 gene expression inhibits growth of the low grade non Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1996; 3: 207–12.
- Ward M, Pioli P, Ayello J, et al. Retroviral transfer and expression of the human multiple drug resistance(MDR) gene in peripheral blood progenitor cells. Clin Cancer Res 1996; 2: 873–6.
- Ueki T, Nakata K, Mawatari F, et al. Retrovirus-mediated gene therapy for human hepatocellular carcinoma trans-planted in athymic mice. Int J Mol Med 1998; 1: 671–5.
- Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Sys-temic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune compo-nent. Cancer Res 1994; 54: 6228–34.
- Culver KW, Ram Z, Walbridge S, Ishii H. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–2.
- Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors. Cancer Res 1993; 53: 83–8.
- Thomas SM, Naresh KN, Wagle AS, Mulherkar R. Preclini-cal studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Res 1998; 18: 4393–8.
- Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum Gene Ther 1998; 9: 2595–604.
- Klatzmann D, Cherin P, Bensimon G, et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma. Study group on gene therapy of metastatic melanoma. Hum Gene Ther 1998; 9: 2585–94.
- Moolten F, Wells JM, Mroz PJ. Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes simplex thymidine kinase genes. Cancer Lett 1992; 64: 257–63.
- Oldfield EH, Culver KW, Ram Z, Blease RM. A clinical protocol: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39–69.
- Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastasis after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024–8.
- Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-pro-ducer cells for treatment of experimental brain tumors. Sci-ence 1992; 256: 1550–2.
- Vile RG, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994; 1: 88–98.
- Welsh RM, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumor viruses. Nature 1975; 257: 612–4.
- Freeman SM, Abboud CN, Whartenby KA, et al. The by-stander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–83.
- Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998; 5: 1705–11.
- Estin D, Li M, Spray D, Wu JK. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery 1999; 44: 361–8.
- Duflot-Dancer A, Piccoli C, Rolland A, Yamasaki H, Mesnil M. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther 1998; 5: 1372–8.
- Mcmasters RA, Saylors RL, Jones KE, Hendrix ME, Moyer MP, Drake RR. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin 43 gap junction formation. Hum Gene Ther 1998; 9: 2253–61.
- Colombo BM, Benedetti S, Ottolenghi S, et al. The bystander effect: association of U-87 cell death with ganciclovir-medi-ated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763–72.
- Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348–52.
- Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373–84.
- Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experi-mental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054–7.